Eiger BioPharmaceuticals, Inc. (EIGR)

$1.6398

+0.22 (+15.48%)
Rating:
Recommendation:
Neutral
Symbol EIGR
Price $1.6398
Beta 1.758
Volume Avg. 0.95M
Market Cap 72.273M
Shares () -
52 Week Range 0.96-10.021
1y Target Est -
DCF Unlevered EIGR DCF ->
DCF Levered EIGR LDCF ->
ROE -106.48% Strong Sell
ROA -64.98% Strong Sell
Operating Margin -
Debt / Equity 83.56% Buy
P/E -
P/B 0.92 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EIGR news


Mr. David Cory
Healthcare
Biotechnology
NASDAQ Global Market

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.